Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 19 - Drugs for skeletal disorders
Patents for A61P 19 - Drugs for skeletal disorders (81,981)
10/2000
10/05/2000WO2000058513A1 49 human secreted proteins
10/05/2000WO2000058494A1 50 human secreted proteins
10/05/2000WO2000058483A2 Protozoan expression system
10/05/2000WO2000058473A2 Nucleic acids including open reading frames encoding polypeptides; 'orfx'
10/05/2000WO2000058466A2 Protease resistant flint analogs
10/05/2000WO2000058463A1 Polynucleotide and deduced amino acid sequences from stromal cells
10/05/2000WO2000058355A1 50 human secreted proteins
10/05/2000WO2000058350A1 49 human secreted proteins
10/05/2000WO2000058348A1 Treatment of bone disorders with adrenomedullin or adrenomedullin agonists
10/05/2000WO2000058339A2 50 human secreted proteins
10/05/2000WO2000058334A1 50 human secreted proteins
10/05/2000WO2000058307A2 Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands
10/05/2000WO2000058305A1 Novel compounds
10/05/2000WO2000058304A1 Heterocyclic sulfonamide derivatives
10/05/2000WO2000058296A1 Protease inhibitors
10/05/2000WO2000058295A2 Compounds and methods for treatment of asthma, allergy and inflammatory disorders
10/05/2000WO2000058279A1 Diaryl derivatives and their use as medicaments
10/05/2000WO2000058278A1 β-AMINO ACID DERIVATIVES
10/05/2000WO2000057920A2 Method for expressing proteins
10/05/2000WO2000057916A1 Sphingomyelin containing preparation for the enhancement of tumor therapy
10/05/2000WO2000057903A2 48 human secreted proteins
10/05/2000WO2000057901A1 Modulation of vascular permeability by means of tie2 receptor activators
10/05/2000WO2000057897A1 Use of a lectin or conjugates for modulation of c-fibre activity
10/05/2000WO2000026243A3 Transmembrane 4 proteins
10/05/2000WO2000025602A3 Use of calcareous material for foodstuff and cosmetic material
10/05/2000WO2000005249A3 Synthetic peptides and methods of use for autoimmune disease therapies
10/05/2000CA2707691A1 Sphingomyelin containing preparation
10/05/2000CA2383592A1 2384891 acids including open reading frames encoding polypeptides; orfx
10/05/2000CA2368951A1 50 human secreted proteins
10/05/2000CA2368719A1 50 human secreted proteins
10/05/2000CA2368700A1 49 human secreted proteins
10/05/2000CA2368641A1 Use of a lectin or conjugates for modulation of c-fibre activity
10/05/2000CA2368477A1 Polynucleotide and deduced amino acid sequences from stromal cells
10/05/2000CA2368467A1 50 human secreted proteins
10/05/2000CA2368442A1 48 human secreted proteins
10/05/2000CA2368302A1 49 human secreted proteins
10/05/2000CA2368281A1 50 human secreted proteins
10/05/2000CA2368113A1 Protozoan expression system
10/05/2000CA2368090A1 Compounds and methods for treatment of asthma, allergy and inflammatory disorders
10/05/2000CA2367882A1 Treatment of bone disorders with adrenomedullin or adrenomedullin agonists
10/05/2000CA2366305A1 Method for expressing proteins
10/05/2000CA2365401A1 Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands
10/05/2000CA2361366A1 Novel compounds
10/05/2000CA2361016A1 Diaryl derivatives and their use as medicaments
10/04/2000EP1041072A1 Dioxocyclopentyl hydroxamic acids
10/04/2000EP1040838A1 Stable aqueous EM 12 solution
10/04/2000EP1040833A1 Bone resorption suppressing agent
10/04/2000EP1040196A2 Transgenic animal model for degenerative diseases of cartilage
10/04/2000EP1040111A1 Integrin receptor antagonists
10/04/2000EP1040100A1 Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors
10/04/2000EP1040099A1 Azepine or larger medium ring derivatives and their use as pharmaceuticals
10/04/2000EP1040098A1 Integrin receptor antagonists
10/04/2000EP1039911A1 MORPHOLINO-N-ETHYL ESTER PRODRUGS OF INDOLE sPLA 2 INHIBITORS
10/04/2000EP1039903A1 Il-8 receptor antagonists
10/04/2000EP1039893A1 Pharmaceutical compositions containing an omega-3 fatty acid oil
10/04/2000EP1019040A4 INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS
10/04/2000EP0766672B1 Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors
10/04/2000EP0690719B1 Dry mix formulation for bisphosphonic acids
10/04/2000CN1268373A Hanshigutonging medicine for curing arthralgia caused by cold-dampness
10/04/2000CN1268368A Chinese herb medicine preparation for curing prolapse of lumbar intervertebral disk
10/04/2000CN1268360A Medicated liquor for curing rheumatism
10/04/2000CN1057013C Novel 1 L-2 receptor-specific human immunoglobins
10/04/2000CN1057009C Mecicinal liquor for curing rheumatism
10/04/2000CN1056999C Traditional Chinese medicine bolus for treating necrosis of head of femur
10/04/2000CN1056994C External-use medicated ointment for treating necrosis of head of femur
10/04/2000CN1056992C Medicated wine for curing rheumarthritis and rheumatoid arthritis and its prepn. process
10/04/2000CN1056989C External use medicine for traumatic injuries
10/04/2000CN1056988C Traditional Chinese medicine for curing arthralgia-syndrome
10/03/2000US6127559 2-alkyl-19-nor-vitamin D compounds
10/03/2000US6127427 Active hydroxamic acids involved in tissue degradtion and also are inhibitors of the release of tumour necrosis factor from cells; rheumatoid arthritis, osteoarthritis, osteopenias such as osteoporosis, periodontitis, vision defects
10/03/2000US6127423 Phenylamidine derivatives, a process for preparing the same and their use as medicaments
10/03/2000US6127404 Tissue selective compounds in the treatment of endometrial proliferation
10/03/2000US6127391 Compounds with growth hormone releasing properties
10/03/2000US6127387 Use of CD4-binding small molecules to inhibit immune responses
10/03/2000US6127365 Tachykinin antagonists for treatment of pain, inflammation, migraine, emesis and postherpetic neuralgia.
10/03/2000US6127348 Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
10/03/2000US6126939 Anti-inflammatory dipeptide and pharmaceutical composition thereof
09/2000
09/30/2000CA2302886A1 A stable aqueous solution of em 12
09/28/2000WO2000056910A1 Retroviral vectors comprising functional and non-functional splice donor and splice acceptor sites
09/28/2000WO2000056891A2 Human transmembrane proteins
09/28/2000WO2000056889A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same
09/28/2000WO2000056881A1 48 human secreted proteins
09/28/2000WO2000056862A1 Human tumor necrosis factor receptor tr9
09/28/2000WO2000056860A2 Diagnosis and therapy of bone conditions
09/28/2000WO2000056772A1 Human antibodies that bind human il-12 and methods for producing
09/28/2000WO2000056771A1 Recombinant il-18 antagonists useful in treatment of il-18 mediated disorders
09/28/2000WO2000056770A1 ANTI-p53 ANTIBODIES
09/28/2000WO2000056767A1 46 human secreted proteins
09/28/2000WO2000056766A1 47 human secreted proteins
09/28/2000WO2000056755A1 49 human secreted proteins
09/28/2000WO2000056751A1 50 human secreted proteins
09/28/2000WO2000056738A1 Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease
09/28/2000WO2000056729A1 Chemokine recpetor binding heterocyclic compounds
09/28/2000WO2000056710A1 3-(anilinomethylene) oxindoles as protein tyrosine kinase and protein serine/threonine kinase inhibitors
09/28/2000WO2000056709A1 Indolinone compounds as kinase inhibitors
09/28/2000WO2000056704A1 Hydroxamic and carboxylic acid derivatives
09/28/2000WO2000056405A2 Human tumor necrosis factor receptor-like 2
09/28/2000WO2000056357A2 Staphylococcus antigen and vaccine
09/28/2000WO2000056356A2 Induction of antigen-specific unresponsiveness by glioblastoma culture supernatants (gcs)
09/28/2000WO2000056350A2 Methods of use of beta 1-integrin inhibitors
1 ... 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 ... 820